Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid.

Abstract

Interstitial cystitis is a chronic benign disease of the bladder that causes bothersome and debilitating symptoms and mainly affects women. Since interstitial cystitis (IC) might result from a defective glycosaminoglycan layer of the bladder epithelium, we conducted a trial of hyaluronic acid (HA), used intravesically, to test its activity in the treatment of this disease. A total of 10 patients with typical findings of IC were included. Following bladder catheterisation, the patients received a dose of 40 mg, weekly for 6 weeks, and then monthly. Response to therapy was evaluated by comparing the pre-treatment and post-treatment symptom scores and voiding diaries. There was a 30% positive response rate at week 6, which was maintained until week 24. No significant local or general side-effects were noted during the course of treatment. Although we recorded a low incidence of success in our group of patients, the results of our limited study were satisfactory in the group of responsive patients (30%), who had no relapses during the observation period of 6 months. The intravesical administration of HA was well tolerated in all cases.

• Authors: D Porru, G Campus, D Tudino, E Valdes, A Vespa, R M Scarpa, E Usai
• Journal: Urologia internationalis (Urol Int) Vol. 59 Issue 1 Pg. 26-9 ( 1997) ISSN: 0042-1138 [Print] Switzerland
• PMID: 9313320 (Publication Type: Journal Article)

Chemical References

• Hyaluronic Acid

Topics

• Administration, Intravesical
• Adult
• Cystitis, Interstitial (diagnosis, drug therapy)
• Female
• Humans
• Hyaluronic Acid (administration & dosage)
• Middle Aged